{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Kite Pharma, Inc. (\"Kite\") located in Santa Monica, CA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2019/07/12/2019-14822.html","cfr_references":[],"citation":"84 FR 33270","comment_url":null,"comments_close_on":"2019-07-29","correction_of":null,"corrections":[],"dates":"Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 29, 2019 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2019-14822","effective_on":null,"end_page":33270,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2019/07/12/2019-14822.xml","html_url":"https://www.federalregister.gov/documents/2019/07/12/2019-14822/prospective-grant-of-an-exclusive-patent-license-allogeneic-therapy-using-bicistronic-chimeric","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2019-14822?publication_date=2019-07-12","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2019-07-12/2019-14822/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":460,"last_updated":"2026-06-25 08:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-07-12/pdf/2019-14822.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-14822.pdf?1562849118","publication_date":"2019-07-12","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2019/07/12/2019-14822.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T23:18:42Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":33270,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Bicistronic Chimeric Antigen Receptors Targeting CD19 and CD20","toc_doc":"Allogeneic Therapy Using Bicistronic Chimeric Antigen Receptors Targeting CD19 and CD20","toc_subject":"Prospective Grant of an Exclusive Patent License:","topics":[],"type":"Notice","volume":84}